Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies

• Published in: Virus genes 2024-12, Vol.60 (6), p.592-602
• Main Authors: Nair, Dakshina M., Vajravelu, Leela Kakithakara, Thulukanam, Jayaprakash, Paneerselvam, Vishnupriya, Vimala, Poornima Baskar, Lathakumari, Rahul Harikumar
• Format: Article
• Language: English
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; chemical bonding; Chronic infection; Circular DNA; Cirrhosis; CRISPR; CRISPR-Cas systems; CRISPR-Cas Systems - genetics; Gene Editing - methods; Genetic Therapy - methods; genome; Hepatitis B; Hepatitis B - genetics; Hepatitis B - therapy; Hepatitis B - virology; Hepatitis B virus; Hepatitis B virus - genetics; Hepatitis B, Chronic - therapy; Hepatitis B, Chronic - virology; Hepatocellular carcinoma; hepatoma; Humans; Immune response; Infections; liver; Liver diseases; Medical innovations; Medical Microbiology; pathogenesis; Plant Sciences; Public health; Review Paper; therapeutics; Virology; Virus Replication - genetics; Viruses
• ISSN: 0920-8569; 1572-994X; 1572-994X
• DOI: 10.1007/s11262-024-02105-3

Hepatitis B virus (HBV) infection remains a significant global health challenge, with chronic HBV leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Current treatments often fail to eradicate the virus, highlighting the need for innovative therapeutic strategies. The CRISPR/Cas9 system has emerged as a dynamic tool for precise genome editing and presents a promising approach to targeting and eliminating HBV infection. This review provides a comprehensive overview of the advances, challenges, and delivery strategies associated with CRISPR/Cas9-based therapies for HBV. We begin by elucidating the mechanism of the CRISPR/Cas9 system and then explore HBV pathogenesis, focusing on the role of covalently closed circular DNA (cccDNA) and integrated HBV DNA in maintaining chronic infection. CRISPR/Cas9 can disrupt these key viral reservoirs, which are critical for persistent HBV replication and associated liver damage. The application of CRISPR/Cas9 in HBV treatment faces significant challenges, such as off-target effects, delivery efficiency, and immune responses. These challenges are addressed by examining current approaches to enhance the specificity, safety, and efficacy of CRISPR/Cas9. A future perspective on the development and clinical translation of CRISPR/Cas9 therapies for HBV is provided, emphasizing the requirement for further research to improve delivery methods and ensure durable safety and effectiveness. This review underscores the transformative potential of CRISPR/Cas9 in combating HBV and sets the stage for future breakthroughs in the field.